Translating these findings to ICH, future prospective clinical studies are imperative to determine whether peripheral or central IL-11 levels can serve as a reliable biomarker for predicting hematoma expansion, functional outcome, or guiding targeted anti-inflammatory therapy. This evidence concerns the gene IL11 and hematoma.